CliffBio
small molecule

REVONTO

DANTROLENE SODIUM

Loss of exclusivity—loss of exclusivity
CompanyUSWM, LLC →See this company's full patent-cliff portfolio

Drug detail

Brand nameREVONTO
Active ingredientDANTROLENE SODIUM
Strength20MG/VIAL
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalJuly 2007
Marketing statusRX

More from USWM, LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

REVONTO patent cliff — loss of exclusivity — | CliffBio